Michael Gilman

Outlook Microsoft Office 365 CloudFlare Hosting WordPress.org Google Font API Google Tag Manager Mobile Friendly Remote AI

pharmaceutical manufacturing rna-targeted small molecules rsm medicines drug discovery therapeutic applications rna biology biological targets modulatory mechanisms small molecule drugs rna binding clinical development disease modification covalent modifiers targeted rna degradation oral medicines biotech innovation structure-based drug design rna structure-function relationship druggable rna therapeutic target identification collaborative partnerships pipeline expansion rsm toolkit biopharmaceutical collaborations rna-targeting drug platforms rna structural biology drug design workflow highly selective compounds in vitro pharmacology chemical biology small molecule therapeutics structural bioinformatics dynamic modeling rna & disease biological activity therapeutic proteins precision medicine collaborative research patient-centric approach novel therapeutics rna-targeted therapies rsm discovery innovative drug modalities precision oncology multimodal therapeutic strategies rare diseases neuromuscular diseases cardiovascular conditions neurodegenerative diseases genetic medicines neurology oncology rare genetic disorders myotonic dystrophy type 1 cancer treatment cardiovascular diseases biopharmaceuticals oral bioavailability tryst platform pearl-seq platform undruggable targets innovative therapies therapeutic intervention patient impact pharmaceutical partnerships preclinical development systemic delivery cost-efficient manufacturing disease-modifying therapies collaborative approach scientific community venture capital investment transformative medicines pharmaceuticals medical hospital & health care